DL-7'-aminospiro-2,5-dione | 106094-81-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: DL-7'-aminospiro-2,5-dione
• 英文别名: (+/-)-7'-amino-3',4'-dihydro-1'H-spiro[imidazolidine-4,2'-naphthalene]-2,5-dione；6-aminospiro[2,4-dihydro-1H-naphthalene-3,5'-imidazolidine]-2',4'-dione
• CAS: 106094-81-9
• 化学式: C₁₂H₁₃N₃O₂
• 分子量: 231.254
• InChiKey: DJPBCXZLURSUET-UHFFFAOYSA-N

物化性质

• 密度：
  1.41±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  84.2
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  DL-7'-aminospiro-2,5-dione 生成 DL-7'-spiro-2,5-dione
  参考文献：
  名称：

  VISTICA, DAVID T.

  摘要：

  DOI：
• 作为产物：
  描述：

  替群妥英 在 palladium on activated charcoal 氢气 、 硝酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 25.0 ℃ 、206.84 kPa 条件下， 反应 2.5h， 生成 DL-7'-aminospiro-2,5-dione
  参考文献：
  名称：

  系统L特定氨基酸氮芥末的选择性细胞毒性。

  摘要：

  DL-2-氨基-7-双[（2-氯乙基）氨基] -1,2,3,4-四氢-2-萘甲酸和DL-2-氨基-5-双[（2 -氯乙基）氨基] -1，2，3，4-四氢-2-萘甲酸+++酸。通过对相应的nitrospirohydantoin前体2和3进行13 C NMR光谱的选择性质子解偶联，可以确定双（2-氯乙基）氨基侧链连接位点的正确分配，这是通过硝化β-四氢萘酮获得的乙内酰脲。将两种靶化合物6和7设计为能够通过亮氨酸优先转运系统（系统L）选择性转运入肿瘤细胞的肿瘤特异性试剂。系统L特定底物2-氨基-双环[2.2。]的初始传输速率的抑制分析。1]庚烷-2-羧酸（BCH）的6和7表明，在鼠L1210白血病细胞（Ki = 0.2 microM）中，7-取代的异构体6是该转运系统的极为有效的竞争性抑制剂。对该化合物的选择性进行评估表明，与原型氨基酸氮芥子气L-苯丙氨酸芥子气（L-PAM）相比，该化合物具有增

  DOI：

  10.1021/jm00386a017

文献信息

• Monocyclic anilide spirohydantoin cgrp receptor antagonists
  申请人：Bell M. Ian

  公开号：US20060148779A1

  公开（公告）日：2006-07-06

  The present invention is directed to compounds that are antagonists of CGRP receptors and that are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及与CGRP受体拮抗的化合物，这些化合物在治疗或预防CGRP参与的疾病，如头痛、偏头痛和群头痛方面是有用的。本发明还涉及包含这些化合物的药物组合物，以及在预防或治疗CGRP参与的这些疾病中使用这些化合物和组合物的用途。
• Aryl spirohydantoin cgrp receptor antagonists
  申请人：Bell M. Ian

  公开号：US20060189593A1

  公开（公告）日：2006-08-24

  The present invention is directed to compounds that are antagonists of CGRP receptors and that are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及对CGRP受体的拮抗剂化合物，这些化合物可用于治疗或预防CGRP参与的疾病，如头痛、偏头痛和群集性头痛。本发明还涉及包含这些化合物的制药组合物和使用这些化合物和组合物预防或治疗CGRP参与的这些疾病。
• Bicyclic anilide spirohydantoin cgrp receptor antagonists
  申请人：Bell M. Ian

  公开号：US20060211712A1

  公开（公告）日：2006-09-21

  The present invention is directed to compounds of the formula: that are antagonists of CGRP receptors and that are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及以下公式的化合物： 该化合物是CGRP受体拮抗剂，可用于治疗或预防CGRP参与的疾病，例如头痛，偏头痛和集群性头痛。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗CGRP参与的这些疾病中使用这些化合物和组合物。
• IMMUNOGENIC COMPOSITIONS FOR GRAM POSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE
  申请人：Bell Ian M.

  公开号：US20090221535A1

  公开（公告）日：2009-09-03

  The present invention is directed to compounds of Formula I: I (where A 1 , A 2 , B 1 , B 2 , B 3 , B 4 , D 1 , D 2 , T, U, V, W, X, Y, Z. R 4 , R 5a ?, R 5b , R 5c , R 6 , m and n are defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及式I的化合物：I（其中A1、A2、B1、B2、B3、B4、D1、D2、T、U、V、W、X、Y、Z、R4、R5a？、R5b、R5c、R6、m和n在此定义），用作CGRP受体的拮抗剂，用于治疗或预防CGRP参与的疾病，如头痛、偏头痛和群头痛。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在预防或治疗CGRP参与的这些疾病中的使用。
• Spirohydantoin Aryl Cgrp Receptor Antagonists
  申请人：Bell Ian M.

  公开号：US20090239870A1

  公开（公告）日：2009-09-24

  Compounds of formula I: (wherein variables A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , B, E 1 , E 2 , E 3 , E 4 , E 5 , G 1 , G 2 and R 6 are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  公式I的化合物：（其中变量A1，A2，A3，A4，A5，A6，A7，B，E1，E2，E3，E4，E5，G1，G2和R6如本文所述），这些化合物是CGRP受体拮抗剂，可用于治疗或预防CGRP参与的疾病，如偏头痛。本发明还涉及包含这些化合物的制药组合物，以及使用这些化合物和组合物在预防或治疗CGRP参与的这些疾病中的应用。